CASI’s business goal is to bring high-quality pharmaceuticals to the growing China market.
EVOMELA® (melphalan) for injection, already marketed in the U.S. by our partner, is intended to be used as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Our import drug registration is currently pending with CFDA with priority review granted.
MARQIBO® (vinCRIStine sulfate LIPOSOME injection), already marketed in the U.S. by our partner, is indicated for the treatment of advanced Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). Our import drug registration is currently pending with CFDA.
ZEVALIN® (ibritumomab tiuxetan), also already marketed in the U.S. by our partner, is indicated for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL).
We intend to develop these 3 FDA approved drugs for import drug registration in the greater China region. For the most up-to-date safety information about these drugs, please refer to our partner’s website www.sppirx.com and to:
ENMD-2076, is our proprietary orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase and is ongoing in one Phase 2 clinical study.
CASI-001 and CASI-002 are proprietary preclinical candidates in immuno-oncology.
CASI will continue to aggressively expand its portfolio through in-licensing and acquisition.